Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
1999-09-21
2004-10-12
Smith, Lynette R. F. (Department: 1645)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S348000, C435S362000, C435S365000, C435S367000, C435S252300, C435S252330, C435S252310, C435S254200, C435S254210, C435S320100, C435S069100, C536S023700, C424S164100
Reexamination Certificate
active
06803231
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods of delivering antigens for vaccination with a live vector.
2. Description of the Related Art
One way in which microorganisms can alter their surface properties, allowing a fraction of the population to preadapt to environmental changes, is by varying protein expression through programmed genomic DNA rearrangements (1). Phase, antigenic, or size variation of expressed surface proteins are governed by mechanisms including transposition and DNA inversion. During transposition, a silent gene is activated by movement to an expression site where it displaces the currently expressed gene. In DNA inversion, a segment of DNA is cut, inverted, and then rejoined by a site-specific recombinase. The invertible DNA segment may contain either a promoter that directs expression of fixed structural genes or structural genes controlled by a fixed promoter. Transposition and inversion differ in both the enzymes used and in the number of genes that can be controlled (many versus two).
Campylobacter fetus
, a bacterial pathogen of ungulates and humans, is covered by a paracrystalline surface (S-) layer, composed of high molecular weight S-layer proteins (SLP) that masks most of the underlying gram-negative surface features (2). More than 300 bacterial genera have been described that possess S-layers (3). The S-layer renders
C. fetus
cells resistant to serum killing by prohibiting the binding of C3b (4), and the S-layer proteins themselves may change, permitting antigenic variation (5,6).
These S-layer proteins are encoded by 7-9 tightly clustered and partially homologous promoterless gene cassettes (7,8). Since previous studies show that
C. fetus
can express alternative S-layer proteins (4-6,9), there is only a single promoter for S-layer proteins expression present on a 6.2 kb invertible element (9), and the structural genes flanking the promoter are subject to substitution (9), both the promoter and the eight structural genes (sapA and its homologs) may rearrange strictly by inversion.
Campylobacter fetus
is able to colonize the mucosa of the gastrointestinal and/or genitourinary tracts of mammals, birds and reptiles. Colonization of the wild-type organism lasts for years and can cause disease. Essential for this long term colonization is the ability to produce the S-layer proteins and
Campylobacter fetus
has the means to change the S-layer proteins and thus the crystal struture and the particular forms of antigenicity. This antigenic variation is required for the persistence of the organism in its environmental niche.
Campylobacter fetus
accomplishes this antigenic variation by posssessing 7-9 highly homologous gene cassettes, called sapA homologs (sapA, sapA1, sapA2, etc.) which encode a different S-layer protein. Each of these homologs contains a 5′ region of about 600 base pairs which is completely conserved from homolog to homolog and is necessary for binding of the S-layer protein encoded by that homolog to the lipopolysaccharide molecule anchored in the bacterial outer membrane. The remainder of the open reading frame (ORF) is different for each homolog but semi-conserved regions exist. Wild type
C. fetus
strains are able to rearrange their chromosomal DNA so that the sapA homolog positioned downstream of a unique promoter is then expressed. This rearrangement occurs at a frequency of about 10
−4
and is recA dependent. RecA is a protein encoded by recA and which is involved in homologous recombination and in repair of breaks of DNA strands.
C. fetus
S-layer proteins (SLPs) are secreted in the absence of an N-terminal signal sequence. SLP proteins contain a signal sequence located within the C-terminous of the protein and are secreted through a type I protein secretion system encoded by the sapCDEF operon of four overlapping genes. Analysis of the C-termini of four
C. fetus
SLPs revealed conserved structures that are potential secretion signals. A
C. fetus
sapD mutant neither produced nor secreted SLPs.
E. coli
expressing
C. fetus
sapA and sapCDEF secreted SapA, indicating that the sapCDEF genes were sufficient for SLP secretion.
The prior art is deficient in the lack of effective means of delivering antigens for vaccination with a live vector. The present invention fulfills this longstanding need and desire in the art.
SUMMARY OF THE INVENTION
In one embodiment of the present invention, there is provided a mutant
C. fetus
strain in which each of the cassettes is replaced by a heterologous antigen. The sapA homologs are altered by a DNA cassette inserted so that the encoded SLP represents a chimera between the native SLP and the peptide encoded by the cassette. The inserted DNA cassettes retain 3′ sapA sequences that encode the C-terminal secretion signal sequences in order to ensure secretion of the chimeric protein. Representative examples of cassettes that can be inserted in this fashion include immunogens related to Salmonella,
Campylobacter jejuni, E. coli
0157:H7, human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) as well as other enteric, venereal, or respiratory pathogens of humans, cattle, sheep, poultry, horses, swine, and reptiles. In this embodiment of the present invention, this strain can be used to immunize a host to develop mucosal and systemic immune responses to each of the immunogens.
In another embodiment of the present invention, there is provided a mutant
C. fetus
strain in which all but one of the cassettes are replaced by a heterologous antigen. In this embodiment, one of the cassettes (e.g., sapA2) remains in its native configuration and the others are mutagenized. The advantage of this construction is that it also can induce immunity to
C. fetus
based on the single full-length SLP produced.
In another embodiment of the present invention, there is provided a mutant
C. fetus
strain in which recA is mutagenized. When the RecA protein is not produced, the DNA rearrangements permitting sapA antigenic variation can not occur at any detectable frequency. Thus, the
C. fetus
strain can only produce one of the SLPs encoded by one sapA homolog. This strain can be used, therefore, to colonize the host briefly, i.e. until protective immunity has developed to that homolog. Subsequently, the host immune response eliminates the organism. Thus, this mutant would provide effective immunity against subsequent
C. fetus
infection and is useful for vaccination of ungulates (including sheep, cattle and horses) in which infectious abortion and/or infertility can occur after the wild-type infection.
In another embodiment of the present invention, there is provided a
C. fetus
strain in which recA is mutagenized and the expressed sapA homolog is a chimera involving a heterologous peptide. In this embodiment, a mutagenized sapA homolog expresses a chimeric protein including a heterologous antigen. The strain is then passaged in vitro so that the chimeric homolog is in the expression position and then a recA mutation is made. This strain now essentially expresses only the chimeric protein thus providing a means to immunize a host to that antigen. The duration of colonization in the host is brief and this attenuated
C. fetus
strain allows safe immunization for the selected antigen.
In yet another embodiment of the present invention, there is provided a mixed mutant
C. fetus
strains each including a sapA chimera which is also a recA mutant. In this embodiment, mutants are constructed in which a single sapA homolog is mutagenized to encode a different chimeric protein representing a different heterologous antigen. Each mutant is also RecA-deficient due to mutation in recA. A host is inoculated with a mixture of two or more of these strains to provide immunization to the requisite antigens. Each strain is short-lived in the immunized host.
In another embodiment of the present invention there is provided a strain of
Blaser Martin
Dworkin Joel
Thompson Stuart A.
Adler Benjamin Aaron
Portner Ginny Allen
Smith Lynette R. F.
Vanderbilt University
LandOfFree
Method of delivering antigens for vaccination with a live... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of delivering antigens for vaccination with a live..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of delivering antigens for vaccination with a live... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3280394